摘要
目的探讨诺和锐30对2型糖尿病胰岛素抵抗及相关炎性因子的影响。方法将2014年6月—2015年6月收治的2型糖尿病106例依据是否愿意接受胰岛素治疗分为观察组和对照组,每组53例。两组均给予健康宣教、饮食控制、运动、血糖监测等干预,口服二甲双胍控制血糖,观察组同时给予诺和锐30治疗。治疗3个月后,观察两组临床效果,比较治疗前后血糖胰岛素分泌指数(HOME-β)、胰岛素抵抗指数(HOME-IR)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及血清超敏C反应蛋白(hs-CRP)水平的变化。结果观察组总有效率高于对照组(P<0.05)。观察组治疗后空腹血糖、餐后2 h血糖、糖化血红蛋白、HOMA-IR、IL-6、TNF-α及hs-CRP水平低于对照组,HOMA-β水平高于对照组(P<0.05)。结论诺和锐30治疗2型糖尿病能有效降低血糖水平,改善胰岛素抵抗,降低相关炎性因子水平,临床治疗效果好。
Objective To investigate effects of Novo Mix 30 on insulin resistance and inflammatory factors of patients with type 2 diabetes mellitus. Methods A total of 106 patients with type 2 diabetes mellitus were divided into observation group and control group（ n = 53 for each group） according to whether patients were willing to receive insulin treatment or not. All patients received intervention treatments such as health education,alimentary control,exercise and blood glucose monitoring,and oral Metformin was given for controlling blood glucose. Meanwhile,observation group was treated with Novo Mix 30. After 3 months of treatment,in two groups,clinical effects were observed,and changes of insulin secretion index（ HOME-β）,insulin resistance index（ HOME-IR）,interleukin-6（ IL-6）,tumor necrosis factor-α（ TNF-α） and serum high sensitivity C reactive protein（ hs-CRP） levels before and after treatment were compared. Results Compared with those in control group,total effective rate of treatment was higher in observation group（ P〈0. 05）; after treatment,levels of fasting plasma glucose,2 h postprandial glucose,glycated hemoglobin,HOMA-IR IL-6,TNF-α and hs-CRP levels were lower,while HOME-β level was higher（ P〈0. 05）. Conclusion Novo Mix 30 in treatment of patients with type 2 diabetes mellitus can effectively decrease blood glucose level,improve insulin resistance and reduce levels of related inflammatory factors with good clinical effect.
出处
《解放军医药杂志》
CAS
2016年第10期92-94,99,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
陕西省科学技术研究发展计划项目(2013k12_01_23)
关键词
糖尿病
2型
天冬胰岛素
胰岛素抵抗
炎症因子
Diabetes mellitus
type 2
Insulin aspart
Insulin resistance
Inflammatory factor
